Frequency, clinical features and differential response to therapy of concurrent ALK/EGFR alterations in Chinese lung cancer patients.
Liu J, Mu Z, Liu L, Li K, Jiang R, Chen P, Zhou Q, Jin M, Ma Y, Xie Y, Xiang J, Li B, Ma Y, Mao X, Zhang L, Zhang T, Wu D.
Liu J, et al. Among authors: xie y.
Drug Des Devel Ther. 2019 May 23;13:1809-1817. doi: 10.2147/DDDT.S196189. eCollection 2019.
Drug Des Devel Ther. 2019.
PMID: 31213769
Free PMC article.